Literature DB >> 26709128

CpG-Oligodeoxynucleotides in Chronic Rhinosinusitis Cell Culture.

Richard Birk1, Christoph Aderhold2, Karl Hörmann2, Angela Wenzel2, Benedikt Kramer2, Till Eschenhagen2, J Ulrich Sommer2.   

Abstract

UNLABELLED: In chronic rhinosinusitis (CRS) an important feature is the infiltration of eosinophils, triggered by T-helper type 2 cells (TH2). Binding of the CpG oligodeoxynucleotide (CpG-ODN) ligand to toll-like receptor 9 (TLR9) induces a shift from a TH2- to a TH1-type response. We evaluated the hypothesis that CpG-ODN could reduce the predominantly TH2-driven response in our cultures.
MATERIALS AND METHODS: Twenty samples from CRS patients with (CRSwNP) and without nasal polyposis (CRSsNP) were cultivated. The expression of interleukin 5 (IL-5), eotaxin 3 and matrix metalloprotease 9 (MMP-9) were evaluated with and without CpG-ODN.
RESULTS: Addition of CpG did not influence the expression of IL-5 and eotaxin-3 DNA. Elevated MMP-9 expression in cultures from CRSwNP and CRSsNP patients could be established.
CONCLUSION: CpG does not reduce the attraction of eosinophils since no reduced IL-5 expression was measured in our cultures. Yet, MMP-9 - an important factor in tissue remodelling - was elevated in cultures from CRS patients.
Copyright © 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Chronic rhinosinusitis; CpG-ODN; IL-5; MMP-9; eotaxin 3

Mesh:

Substances:

Year:  2016        PMID: 26709128

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Intramuscular primary immunization by nucleic acid vaccine pcDNA/Gpd-IL-2 and enhanced immunization with mucosal adjuvant CpG-ODN and Gpd-IL-2 recombinant protein effectively induced strong mucosal immune responses and immune protective effects against Treponema pallidum skin infection.

Authors:  Xiaohong Zhang; Tie Zhao; Tiebing Zeng; Ning Wu; Yongjian Xiao; Shuangquan Liu; Jian Yu; Chuanhao Jiang; Lin Gan; Meixia Deng; Xi Luo; Feijun Zhao
Journal:  Exp Ther Med       Date:  2018-01-04       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.